RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+30.88%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$330M
AUM Growth
+$330M
(+13%)
Cap. Flow
-$24.8M
Cap. Flow
% of AUM
-7.53%
Top 10 Holdings %
Top 10 Hldgs %
74.02%
Holding
44
New
8
Increased
8
Reduced
11
Closed
8
Top Buys
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$14.4M |
| 2 |
AGEN
Agenus
AGEN
|
$12.3M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$8.68M |
| 4 |
Arrowhead Research
ARWR
|
$8.21M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.84M |
Top Sells
| 1 |
BLUE
bluebird bio
BLUE
|
$35.5M |
| 2 |
Incyte
INCY
|
$19M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$14.3M |
| 4 |
SSRG
SYMMETRY SURGICAL INC COMMON STK
SSRG
|
$12.1M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$6.25M |
Sector Composition
| 1 | Healthcare | 90.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $64.3M | 19.43% | 948,286 +115,737 | +14% | +$7.84M |
|
|
AVXS
2
DELISTED
AveXis, Inc. Common Stock
AVXS
| $34M | 10.29% | 825,980 +349,613 | +73% | +$14.4M |
|
|
AGEN
3
Agenus
AGEN
$133M
| $29.7M | 8.99% | 4,141,644 +1,712,495 | +70% | +$12.3M |
|
|
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $27.8M | 8.41% | 1,170,151 -5,995 | -0.5% | -$143K |
|
|
5
BioCryst Pharmaceuticals
BCRX
$1.74B
| $18.5M | 5.6% | 4,204,579 +1,967,513 | +88% | +$8.68M |
|
|
6
Incyte
INCY
$16.5B
| $18M | 5.45% | 191,151 -201,085 | -51% | -$19M |
|
|
ACHN
7
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $17.9M | 5.41% | 2,208,749 -215,387 | -9% | -$1.74M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11.9M | 3.6% | 2,026,894 | – | – |
|
9
Bristol-Myers Squibb
BMY
$96B
| $11.3M | 3.42% | 209,701 | – | – |
|
10
SPDR Gold Trust
GLD
$107B
| $10.4M | 3.15% | 83,000 | – | – |
|
11
Atara Biotherapeutics
ATRA
$84.6M
| $9.8M | 2.96% | 458,113 -7,761 | -2% | -$166K |
|
|
12
Arrowhead Research
ARWR
$3.05B
| $8.21M | 2.48% | +1,116,777 | New | +$8.21M |
|
13
Heron Therapeutics
HRTX
$207M
| $6.66M | 2.01% | +386,787 | New | +$6.66M |
|
|
VIVE
14
DELISTED
VIVEVE MED INC
VIVE
| $6.06M | 1.83% | 839,274 +24,328 | +3% | +$176K |
|
|
BLUE
15
DELISTED
bluebird bio
BLUE
| $5.95M | 1.8% | 87,734 -524,291 | -86% | -$35.5M |
|
|
CORI
16
DELISTED
Corium International, Inc.
CORI
| $5.89M | 1.78% | 1,045,747 +192,786 | +23% | +$1.09M |
|
|
IVTY
17
DELISTED
Invuity, Inc
IVTY
| $5.39M | 1.63% | 392,838 +166,796 | +74% | +$2.29M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $5.02M | 1.52% | 1,243,164 -21,063 | -2% | -$85.1K |
|
|
MDCO
19
DELISTED
Medicines Co
MDCO
| $4.64M | 1.4% | +123,000 | New | +$4.64M |
|
20
Omeros
OMER
$283M
| $4.27M | 1.29% | 383,012 -143,776 | -27% | -$1.6M |
|
21
Tactile Systems Technology
TCMD
$297M
| $4.26M | 1.29% | +227,599 | New | +$4.26M |
|
|
JO
22
DELISTED
iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038
JO
| $4.02M | 1.21% | 180,500 +36,300 | +25% | +$808K |
|
23
Regenxbio
RGNX
$451M
| $3.35M | 1.01% | 238,740 -4,044 | -2% | -$56.7K |
|
|
OXFD
24
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $2.96M | 0.9% | +235,900 | New | +$2.96M |
|
|
FPRX
25
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $2.31M | 0.7% | 44,044 -657 | -1% | -$34.5K |
|